Systems Biology Ireland uses HP Extreme Data Storage technology to
advance new drug development
14 October 2009
HP (NYSE:HPQ) has announced it is collaborating with Systems Biology
Ireland (SBI) on life sciences research aimed at providing a powerful
new way to use the strength of computers and mathematics to understand
The SBI research program, enabled by HP scale-out storage technology,
seeks to unravel the complexities of cells through the use of models
that predict biological behaviour.
Modern life sciences research is data intensive, generating
considerable amounts of information that needs to be stored, managed and
retrieved in an instant. SBI is using the multipetabyte storage capacity
of the HP StorageWorks 9100 Extreme Data Storage (ExDS9100) system to
improve the efficiency of research processes.
“The research being undertaken by SBI will aid the development of new
treatments for medical conditions, including various cancers, and allow
for better therapies to be delivered faster and more effectively to
patients,” said David Medina, executive lead, Worldwide Life Sciences
and Pharma Segment, HP.
“The HP ExDS9100 helps make the SBI program possible by driving
efficiency in research and dramatically reducing the complexity and cost
The HP ExDS9100 allows customers to easily manage large amounts of
data, save datacenter space and lower costs. For customers needing high
levels of scalability, such as SBI, the ExDS9100 can hold up to 16
BladeSystem c-Class server blades with hundreds of terabytes of storage
capacity. To save administrative time, the ExDS9100 features a single
management interface that allows complete visibility to the performance
utilization and capacity of servers and storage within the system.
“The next phase of discoveries in biomedical research will be at the
nexus of technology, computation, chemistry, modeling and biology,” said
Professor Walter Kolch, director, Systems Biology Ireland, University
“Extending beyond our storage needs, our collaboration with HP
includes engaging knowledgeable people who understand our business and
this complex industry. By working with HP and other organizations around
the world, we can help speed up the experimentation process and reduce
the number of years it takes to develop a new drug therapy.”
The SBI research program is a collaboration among industry and
academic organizations, including Agilent Technologies, Ark
Therapeutics, HP, Protagen AG, Science Foundation Ireland, Servier,
Siemens Ireland and University College Dublin.
Bookmark this page